Moleculin Biotech Announces Annamycin Shows No Cardiotoxicity in 90 Subjects Across Five Trials.

Moleculin Biotech announced that Annamycin, its next-generation anthracycline, has demonstrated no evidence of cardiotoxicity in 90 subjects across five clinical trials. The data was reviewed by an independent expert affiliated with a leading cancer research institute. The results show promising early activity in treating multiple oncology indications, including acute myeloid leukemia and soft tissue sarcoma.